CytoMed Therapeutics Limited (GDTC) Options Greeks

Options Greeks measure sensitivity to various factors: Delta (price), Gamma (delta change), Theta (time decay), and Vega (volatility). They are essential for risk management and position sizing.

CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $14.2M, listed on NASDAQ, employing roughly 43 people, carrying a beta of -0.17 to the broader market. CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. Led by Chee Kong Choo, public since 2023-04-14.

Options Greeks analysis provides sensitivity measures for price, time, and volatility. No recent options activity for GDTC as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how options Greeks is reported and how to read the data →